Sigyn Therapeutics (SIGY) Income from Discontinued Operations (2018 - 2019)
Sigyn Therapeutics' (SIGY) quarterly Income from Discontinued Operations came in at $238315.0 in Q1 2019, up 287.43% year-over-year from $61511.8 in Q1 2018, and up 4588.04% quarter-over-quarter from -$5310.0 in Q4 2018.
Powered by 
Analysis
Sigyn Therapeutics (SIGY) Income from Discontinued Operations (2018 - 2019) Analysis & Trends
Sigyn Therapeutics has disclosed Income from Discontinued Operations across 2 years of filings, most recently posting $238315.0 for Q1 2019.
- In Q1 2019, Income from Discontinued Operations rose 287.43% year-over-year to $238315.0; the TTM figure through Dec 2019 stood at $238315.0 (up 175.52% YoY), while the FY2019 annual figure was $238315.0, up 175.66% from the prior year.
- Income from Discontinued Operations came in at $238315.0 for Q1 2019 at Sigyn Therapeutics, up from -$5310.0 in the prior quarter.
- In the past five years, Income from Discontinued Operations ranged from a high of $238315.0 in Q1 2019 to a low of -$155660.0 in Q2 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 181.55 Bn | 175.95 Bn | 7.27 Bn | - |
| 2 | Intuitive Surgical | 127.44 Bn | 122.22 Bn | 1.96 Bn | - |
| 3 | Medtronic | 117.25 Bn | 108.43 Bn | 6.34 Bn | - |
| 4 | Stryker | 105.32 Bn | 101.85 Bn | 4.50 Bn | - |
| 5 | Boston Scientific | 64.67 Bn | 64.13 Bn | 3.85 Bn | - |
| 6 | Edwards Lifesciences | 49.86 Bn | 45.61 Bn | 1.35 Bn | - |
| 7 | Alcon | 33.13 Bn | 31.67 Bn | 1.68 Bn | - |
| 8 | Dexcom | 32.24 Bn | 30.29 Bn | 830.00 Mn | - |
| 9 | Steris | 20.76 Bn | 20.28 Bn | 684.20 Mn | - |
| 10 | Sigyn Therapeutics | 48,161.31 | -37,409.69 | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2019 | 238,315.00 |
| Dec 31, 2018 | -5,310.00 |
| Sep 30, 2018 | -27,448.00 |
| Jun 30, 2018 | -155,660.00 |
| Mar 31, 2018 | -127,149.00 |